Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Achim Rittmeyer, Fabrice Barlési, Daniel Waterkamp, +22

The Lancet

Non-small-cell Lung CancerMedicineMetronomic TherapyClinical TrialsPathology +10

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

Louis Fehrenbacher, Alexander I. Spira, Marcus Ballinger, +15

The Lancet

Non-small-cell Lung CancerMedicineMetronomic TherapyClinical TrialsBronchial Neoplasm +7

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

Howard West, Michael McCleod, Maen Hussein, +17

The Lancet Oncology

MedicineMetronomic TherapyPharmacologyPathologyBronchial Neoplasm +7

Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab

David R. Gandara, Sarah Paul, Marcin Kowanetz, +19

Nature Medicine

OncologyPathologyBronchial NeoplasmClinical BenefitCancer Genetics +3

Randomized Phase III Trial of Maintenance Bevacizumab With or Without Pemetrexed After First-Line Induction With Bevacizumab, Cisplatin, and Pemetrexed in Advanced Nonsquamous Non–Small-Cell Lung Cancer: AVAPERL (MO22089)

Fabrice Barlési, Arnaud Scherpereel, Achim Rittmeyer, +10

Journal of Clinical Oncology

Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials

Myriam Chalabi, Andrés F. Cardona, Deepti R. Nagarkar, +7

Annals of Oncology

Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non–Small Cell Lung Cancer

Louis Fehrenbacher, Joachim von Pawel, Keunchil Park, +20

Journal of Thoracic Oncology

MedicineMetronomic TherapyPathologyBronchial NeoplasmAtezolizumab Versus Docetaxel +5

Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial

Enriqueta Felip, Nasser K. Altorki, Caicun Zhou, +13

Annals of Oncology

Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non–Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers

Solange Peters, Rolf A. Stahel, Lukas Bubendorf, +14

Clinical Cancer Research

Atezolizumab Versus Docetaxel in Pretreated Patients With NSCLC: Final Results From the Randomized Phase 2 POPLAR and Phase 3 OAK Clinical Trials

Julien Mazières, Achim Rittmeyer, Shirish M. Gadgeel, +8

Journal of Thoracic Oncology